Archive · 19 Sep 2026
Nestle India Denies FSSAI Baby Formula Legal Action Report
Nestle India makes some baby-food products, including NAN Excella Pro and Lactogen Pro.
A report said India’s food regulator had taken legal action over these products.
Nestle said that report was incorrect and that its products and labels follow the rules.
The regulator, however, reportedly opened three cases after reviewing product claims and testing a formula sample.
Some claims mentioned five HMOs, whey protein, and easy digestion.
A tested follow-up formula sample also had less Biotin than required, according to the article.
Nestle said it had provided explanations and scientific support for the label statements.
The disagreement matters because parents need reliable information about baby-food ingredients and nutrition.
The proceedings do not mean that every Nestle infant product is unsafe.
Nestle India called a September 18, 2026 report about FSSAI action against its baby formula products factually incorrect.
The company said NAN Excella Pro and Lactogen Pro comply with regulations and their labels were approved by an FSSAI expert committee.
FSSAI reportedly filed three adjudication cases over promotional claims and a follow-up formula sample with inadequate Biotin.
Nestle India shares closed 1.4% lower at ₹1,353.10 amid concerns about the regulatory findings.
The episode highlights the importance of accurate infant-food claims and nutrition levels, but does not establish that all Nestle infant products are unsafe.
- Who
- Nestle India and the Food Safety and Standards Authority of India (FSSAI).
- What
- A dispute over reported regulatory action involving infant formula claims and a sample allegedly below the required Biotin level.
- When
- Nestle India issued its clarification on September 18, 2026.
- Where
- The matter concerns infant nutrition products sold in India and was raised through Indian stock-exchange disclosures.
- Why
- FSSAI identified alleged promotional and nutrition-compliance issues, while Nestle said its products and labels comply with applicable regulations.
Nestle India's Position
FSSAI's Reported Findings
Regulatory compliance
Nestle India's Position
Nestle India said its products fully comply with applicable regulations and that the report about legal action was factually incorrect.
FSSAI's Reported Findings
FSSAI reportedly initiated three adjudication cases after identifying alleged compliance issues involving infant-food promotions and nutrition standards.
Product-label claims
Nestle India's Position
Nestle said the statements on the labels were factual, supported by scientific literature, and approved by an FSSAI expert committee.
FSSAI's Reported Findings
FSSAI reportedly determined that claims about five HMOs, whey protein, and whey protein’s digestibility breached restrictions on promotional material for infant foods.
Biotin level
Nestle India's Position
Nestle’s clarification focused on regulatory compliance and did not accept the reported characterization of the matter as having a material impact on the company.
FSSAI's Reported Findings
FSSAI reportedly found a follow-up formula sample below the prescribed Biotin level, with a referral laboratory also finding it non-conforming.
- Products mentioned
- NAN Excella Pro and Lactogen Pro, along with a Nestle follow-up formula sample.
- Regulatory authority
- Food Safety and Standards Authority of India (FSSAI).
- Cases
- FSSAI reportedly filed three adjudication cases concerning Infant Nutrition, NAN Excella and Lactogen.
- Claims examined
- Claims involving “5 HMOs,” “Whey Protein,” and whey protein being easy to digest.
- Laboratory finding
- A follow-up formula sample, including after referral-laboratory re-analysis, was reported to have Biotin below the prescribed level.
- Share price
- Nestle India closed 1.4% lower at ₹1,353.10.
- Company response
- Nestle said the products and labels comply with regulations and that the labels were approved by an FSSAI expert committee.